Aplastic Anemia

Diseases /

Back to Diseases List

Overview

NCI Definition: Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors. [1]

Clinical Trials

View Clinical Trials for Aplastic Anemia

There are 4 clinical trials for aplastic anemia, of which 4 are open and 0 are completed or closed. Of the trials that contain aplastic anemia as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 2 are no phase specified (2 open).

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most common interventions in aplastic anemia clinical trials.

Drugs Being Investigated in Aplastic Anemia Trials by Recruiting Status

Significant Genes in Aplastic Anemia

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

ASXL1 +

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains BCR status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

CBFB +

CBFB is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains CBFB status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains DEK status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

DNMT3A +

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

IGH +

IGH is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains IGH status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MAF +

MAF is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MAF status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB +

MAFB is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MYH11 +

MYH11 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

PHF6 +

PHF6 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1T1 +

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1T1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TET2 +

TET2 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

WHSC1 +

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [3].

Disease Details

Parent(s)

Anemia

Children

Pure Red Cell Aplasia, Leukoerythroblastosis, and Sideroblastic Anemia

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.